Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,544 Shares

Key Points

• Director Daniel Chard sold 9,544 Medifast shares at an average price of $11.73, totaling $111,951.12, under a pre-arranged Rule 10b5-1 trading plan. He retains 130,609 shares, representing a 6.81% reduction in his holdings.
• Medifast shares recently traded at $11.53, with a market capitalization of approximately $128.9 million and a 52-week range of $9.22 to $14.15. The company remains unprofitable, though its latest quarterly loss of $0.28 per share beat analyst expectations.
• Analyst sentiment is cautious: Medifast has an average “Reduce” rating and a $12 consensus price target, while institutional investors and hedge funds own 95.51% of the stock.

Medifast Inc (NYSE:MED - Get Free Report) Director Daniel Chard sold 9,544 shares of the business's stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $11.73, for a total transaction of $111,951.12. Following the transaction, the director directly owned 130,609 shares in the company, valued at approximately $1,532,043.57. The trade was a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medifast Stock Performance

Shares of MED stock traded down $0.09 on Wednesday, hitting $11.53. The stock had a trading volume of 138,133 shares, compared to its average volume of 113,400. The stock's 50 day moving average is $11.67 and its 200-day moving average is $11.34. The firm has a market capitalization of $128.85 million, a price-to-earnings ratio of -4.95 and a beta of 0.71. Medifast Inc has a 52-week low of $9.22 and a 52-week high of $14.15.

Medifast (NYSE:MED - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.37. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. The firm had revenue of $76.38 million for the quarter, compared to the consensus estimate of $72.70 million. Medifast has set its FY 2026 guidance at -1.750--0.250 EPS and its Q3 2026 guidance at -0.650--0.150 EPS. Equities analysts expect that Medifast Inc will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MED. State of Wyoming raised its stake in shares of Medifast by 19.8% in the 1st quarter. State of Wyoming now owns 6,646 shares of the specialty retailer's stock valued at $68,000 after purchasing an additional 1,097 shares in the last quarter. Ancora Advisors LLC acquired a new position in Medifast in the second quarter worth about $75,000. Quantinno Capital Management LP increased its holdings in Medifast by 15.1% in the first quarter. Quantinno Capital Management LP now owns 56,153 shares of the specialty retailer's stock valued at $572,000 after buying an additional 7,346 shares during the last quarter. Engineers Gate Manager LP increased its holdings in Medifast by 25.9% in the second quarter. Engineers Gate Manager LP now owns 49,829 shares of the specialty retailer's stock valued at $529,000 after buying an additional 10,249 shares during the last quarter. Finally, Ieq Capital LLC acquired a new stake in Medifast during the second quarter valued at approximately $114,000. 95.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MED has been the topic of a number of analyst reports. Weiss Ratings raised Medifast from a "sell (e+)" rating to a "sell (d)" rating in a research report on Monday, August 17th. Zacks Research downgraded Medifast from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 11th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Medifast currently has an average rating of "Reduce" and a consensus target price of $12.00.

Medifast Company Profile

Medifast, Inc NYSE: MED is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development.

The company's product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company's direct-selling model.

Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.